Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CTX110 |
Trade Name | |
Synonyms | CTX-110|CTX 110|anti-CD19 CAR CRISPR-edited CTX110 |
Drug Descriptions |
CTX110 consists of a preparation of allogeneic T-lymphocytes engineered with CRISPR/Cas9 to express a chimeric antigen receptor (CAR) targeting CD19 and to simultaneously remove the endogenous T cell receptor, which potentially reduces GVHD and induces killing of tumor cells overexpressing CD19 (NCI Drug Dictionary). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C165492 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CTX110 | CTX110 | 0 | 1 |